PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR converts PIP2 to PIP3

Stable Identifier
Reaction [transition]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

For the following EGFR-binding ERBB2 KD mutants that were shown to activate PI3K/AKT signaling, it is assumed that heterodimers of these mutants with EGFR, like the wild type ERBB2:EGFR heterodimer, bind to the PI3K complex through GRB2:GAB1, leading to conversion of PIP2 to PIP3:

ERBB2 L755S (Kancha et al. 2011, Cocco et al. 2018, Croessmann et al. 2019);
ERBB2 L755P (Kancha et al. 2011);
ERBB2 I767M (Ng et al. 2015; heterodimerization with EGFR indirectly shown by Bose et al. 2013);
ERBB2 V777L (Kancha et al. 2011);
ERBB2 P780_Y781insGSP (Suzawa et al. 2016);
ERBB2 T798M (Kancha et al. 2011, Rexer et al. 2013);
ERBB2 T798I (Hanker et al. 2017);
ERBB2 T862A (Kancha et al. 2011);
ERBB2 H878Y (Kancha et al. 2011, Hu, Hu et al. 2015, Hu, Wan et al. 2015);
ERBB2 A775_G776insYVMA(Wang et al. 2006);

Activation of PI3K/AKT signaling downstream of the following ERBB2 KD cancer mutants has not been studied and they are annotated as candidates:

ERBB2 G778_P780insGSP
ERBB2 A771_Y772insYVMA

Literature References
PubMed ID Title Journal Year
16843263 HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Wang, SE, Narasanna, A, Perez-Torres, M, Xiang, B, Wu, FY, Yang, S, Carpenter, G, Gazdar, AF, Muthuswamy, SK, Arteaga, CL

Cancer Cell 2006
30314968 Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Croessmann, S, Formisano, L, Kinch, LN, Gonzalez-Ericsson, PI, Sudhan, DR, Nagy, RJ, Mathew, A, Bernicker, EH, Cristofanilli, M, He, J, Cutler, RE, Lalani, AS, Miller, VA, Lanman, RB, Grishin, NV, Arteaga, CL

Clin. Cancer Res. 2019
26375550 Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

Hu, Z, Hu, Y, Liu, X, Xi, R, Zhang, A, Liu, D, Xie, Q, Chen, L

Oncotarget 2015
22046346 Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

Kancha, RK, von Bubnoff, N, Bartosch, N, Peschel, C, Engh, RA, Duyster, J

PLoS ONE 2011
25994018 Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification

Ng, CK, Martelotto, LG, Gauthier, A, Wen, HC, Piscuoglio, S, Lim, RS, Cowell, CF, Wilkerson, PM, Wai, P, Rodrigues, DN, Arnould, L, Geyer, FC, Bromberg, SE, Lacroix-Triki, M, Penault-Llorca, F, Giard, S, Sastre-Garau, X, Natrajan, R, Norton, L, Cottu, PH, Weigelt, B, Vincent-Salomon, A, Reis-Filho, JS

Genome Biol. 2015
26545934 Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations

Suzawa, K, Toyooka, S, Sakaguchi, M, Morita, M, Yamamoto, H, Tomida, S, Ohtsuka, T, Watanabe, M, Hashida, S, Maki, Y, Soh, J, Asano, H, Tsukuda, K, Miyoshi, S

Cancer Sci. 2016
25853726 Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity

Hu, Z, Wan, X, Hao, R, Zhang, H, Li, L, Li, L, Xie, Q, Wang, P, Gao, Y, Chen, S, Wei, M, Luan, Z, Zhang, A, Huang, N, Chen, L

PLoS ONE 2015
28274957 An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer

Hanker, AB, Brewer, MR, Sheehan, JH, Koch, JP, Sliwoski, GR, Nagy, R, Lanman, R, Berger, MF, Hyman, DM, Solit, DB, He, J, Miller, V, Cutler, RE, Lalani, AS, Cross, D, Lovly, CM, Meiler, J, Arteaga, CL

Cancer Discov 2017
23948973 Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2

Rexer, BN, Ghosh, R, Narasanna, A, Estrada, MV, Chakrabarty, A, Song, Y, Engelman, JA, Arteaga, CL

Clin. Cancer Res. 2013
30301790 Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Cocco, E, Javier Carmona, F, Razavi, P, Won, HH, Cai, Y, Rossi, V, Chan, C, Cownie, J, Soong, J, Toska, E, Shifman, SG, Sarotto, I, Savas, P, Wick, MJ, Papadopoulos, KP, Moriarty, A, Cutler, RE, Avogadri-Connors, F, Lalani, AS, Bryce, RP, Chandarlapaty, S, Hyman, DM, Solit, DB, Boni, V, Loi, S, Baselga, J, Berger, MF, Montemurro, F, Scaltriti, M

Sci Signal 2018
Participant Of
Catalyst Activity
Catalyst Activity
phosphatidylinositol-4,5-bisphosphate 3-kinase activity of p-6Y-ERBB2 KD mutants:EGF:p-6Y-EGFR:GRB2:GAB1:PI3K [plasma membrane]
Physical Entity
Normal reaction
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!